AIMS: Bioresorbable polymeric vascular scaffolds may spawn a fourth revolution in percutaneous coronary intervention (PCI) and a novel treatment termed vascular restoration therapy. The principal design considerations for bioresorbable scaffolds are discussed in the context of physiological behaviour using the Bioabsorbable Vascular Solutions (BVS) ABSORB Cohort B scaffold (Abbott Vascular) as an example. METHODS AND RESULTS: The lifecycle of a bioresorbable scaffold is divided into three phases: (1) revascularisation; (2) restoration; and (3) resorption. In the revascularisation phase spanning the first three months after intervention, the bioresorbable scaffold should perform comparably to metallic drug-eluting stents (DES) in terms of deliverability, radial strength, recoil, and neointimal thickening. The ensuing restoration phase is characterised by gradual erosion of radial strength and a loss of structural continuity, where the time scale at which each occurs is related to the hydrolytic degradation rate of the polymer. Natural vasomotion in response to external stimuli is theoretically possible at the end of this phase. Finally, in the resorption phase, the passive implant is systematically resorbed and processed by the body. CONCLUSIONS: Limited clinical data speak to the potential of bioresorbable scaffolds as a new therapy, and future studies will prove critical to inspiring a fourth revolution in PCI.
AIMS: Bioresorbable polymeric vascular scaffolds may spawn a fourth revolution in percutaneous coronary intervention (PCI) and a novel treatment termed vascular restoration therapy. The principal design considerations for bioresorbable scaffolds are discussed in the context of physiological behaviour using the Bioabsorbable Vascular Solutions (BVS) ABSORB Cohort B scaffold (Abbott Vascular) as an example. METHODS AND RESULTS: The lifecycle of a bioresorbable scaffold is divided into three phases: (1) revascularisation; (2) restoration; and (3) resorption. In the revascularisation phase spanning the first three months after intervention, the bioresorbable scaffold should perform comparably to metallic drug-eluting stents (DES) in terms of deliverability, radial strength, recoil, and neointimal thickening. The ensuing restoration phase is characterised by gradual erosion of radial strength and a loss of structural continuity, where the time scale at which each occurs is related to the hydrolytic degradation rate of the polymer. Natural vasomotion in response to external stimuli is theoretically possible at the end of this phase. Finally, in the resorption phase, the passive implant is systematically resorbed and processed by the body. CONCLUSIONS: Limited clinical data speak to the potential of bioresorbable scaffolds as a new therapy, and future studies will prove critical to inspiring a fourth revolution in PCI.
Authors: Natalie Artzi; Abraham R Tzafriri; Keith M Faucher; Geoffrey Moodie; Theresa Albergo; Suzanne Conroy; Scott Corbeil; Paul Martakos; Renu Virmani; Elazer R Edelman Journal: Ann Biomed Eng Date: 2015-08-28 Impact factor: 3.934
Authors: Grzegorz Zuk; Dariusz Ciecwierz; Piotr Drewla; Marcin Gruchała; Juan Luis Gutiérrez-Chico; Milosz Jaguszewski Journal: Cardiol J Date: 2019 Impact factor: 2.737
Authors: Karthik Ramachandran; Tiziana Di Luccio; Artemis Ailianou; Mary Beth Kossuth; James P Oberhauser; Julia A Kornfield Journal: Proc Natl Acad Sci U S A Date: 2018-09-17 Impact factor: 11.205
Authors: Mazen S Albaghdadi; Jian Yang; Jessica H Brown; Neel A Mansukhani; Guillermo A Ameer; Melina R Kibbe Journal: Adv Mater Technol Date: 2017-02-20
Authors: Artemis Ailianou; Karthik Ramachandran; Mary Beth Kossuth; James Paul Oberhauser; Julia A Kornfield Journal: Proc Natl Acad Sci U S A Date: 2016-09-26 Impact factor: 11.205